The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapy
Alessandro Rambaldi(Ospedale Papa Giovanni XXIII), Corrado Tarella(A. O. Ordine Mauriziano di Torino), Giuseppe Gritti(Ospedale Papa Giovanni XXIII), Elena Oldani(Ospedale Papa Giovanni XXIII), Cristina Boschini(Ospedale Papa Giovanni XXIII), Andrea Rossi, Alberto De Crescenzo, Federica Delaini(Ospedale Papa Giovanni XXIII), Caterina Patti(Ospedale Vincenzo Cervello), Marco Ladetto(University of Turin), Daniele Caracciolo(Magna Graecia University), Liliana Devizzi(Fondazione IRCCS Istituto Nazionale dei Tumori), Roberto Passera(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Angela Gueli(A. O. Ordine Mauriziano di Torino), Alessandro M. Gianni(University of Milan), Anna Maria Barbui(Ospedale Papa Giovanni XXIII)
Cited by 65
Related Papers
Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper
|European Respiratory Journal|2004|4.4k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|920